Dakota Gustafson

List of Publications by Citations

Source: https://exaly.com/author-pdf/1616714/dakota-gustafson-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers3,986
citations9
h-index24
g-index24
ext. papers5,907
ext. citations8.3
avg, IF3.78
L-index

#	Paper	IF	Citations
18	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750	16.4	3642
17	Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug testing. <i>Biomaterials</i> , 2020 , 233, 119741	15.6	49
16	Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles. <i>Journal of Extracellular Vesicles</i> , 2019 , 8, 1647027	16.4	48
15	Cellular senescence contributes to age-dependent changes in circulating extracellular vesicle cargo and function. <i>Aging Cell</i> , 2020 , 19, e13103	9.9	42
14	microRNA-guided diagnostics in clinical samples. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016 , 30, 563-575	6.5	42
13	Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017. <i>Journal of Extracellular Vesicles</i> , 2018 , 7, 1473707	16.4	42
12	Overcoming Barriers: The Endothelium As a Linchpin of Coronavirus Disease 2019 Pathogenesis?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020 , 40, 1818-1829	9.4	41
11	Extracellular Vesicles as Protagonists of Diabetic Cardiovascular Pathology. <i>Frontiers in Cardiovascular Medicine</i> , 2017 , 4, 71	5.4	28
10	Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling. <i>Circulation Research</i> , 2020 , 127, 727-743	15.7	19
9	Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2020 , 15, 20-30	4.4	7
8	Combined Cardiac Fluorodeoxyglucose-Positron Emission Tomography/Magnetic Resonance Imaging Assessment of Myocardial Injury in Patients Who Recently Recovered From COVID-19 JAMA Cardiology, 2022,	16.2	5
7	Vasculature-on-a-chip platform with innate immunity enables identification of angiopoietin-1 derived peptide as a therapeutic for SARS-CoV-2 induced inflammation <i>Lab on A Chip</i> , 2022 ,	7.2	4
6	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	4
5	Amyloid transthyretin cardiac amyloidosis: diagnosis and management. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 673-681	2.5	3
4	Cancer therapy-related cardiac dysfunction: is endothelial dysfunction at the heart of the matter?. <i>Clinical Science</i> , 2021 , 135, 1487-1503	6.5	3
3	MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes <i>Cardiovascular Diabetology</i> , 2022 , 21, 31	8.7	3
2	Hiding in Plain Sight: Cardiac Amyloidosis, an Emerging Epidemic. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 373-383	3.8	2

Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies.. *EBioMedicine*, **2022**, 78, 103982

8.8

2